PRINTER'S NO. 488
THE GENERAL ASSEMBLY OF PENNSYLVANIA
SENATE RESOLUTION
No.
52
Session of
2019
INTRODUCED BY SCHWANK, MARTIN, FONTANA, BROWNE, DINNIMAN,
BARTOLOTTA, FARNESE, VOGEL, SCAVELLO, HUGHES, KILLION, COSTA,
BLAKE, FOLMER, J. WARD, STREET, PHILLIPS-HILL, AUMENT,
HUTCHINSON AND MENSCH, MARCH 25, 2019
INTRODUCED AND ADOPTED, MARCH 25, 2019
A RESOLUTION
Designating the month of March 2019 as "Fibromuscular Dysplasia
Awareness Month" in Pennsylvania.
WHEREAS, Fibromuscular dysplasia (FMD) is a disease that
causes abnormal cell growth of the arterial walls in the body
and can lead to areas of narrowing, beading, aneurysms and
tearing of areas of the arterial wall; and
WHEREAS, FMD is most commonly detected accidentally or as a
result of a serious incident because its symptoms, including
hypertension, headaches and dizziness, also commonly have other
causes and are found among much of the general population; and
WHEREAS, There has been little progress in understanding the
disease since the first diagnosis in 1938; and
WHEREAS, There is no known cause or cure and there are no set
protocols for treatment; and
WHEREAS, FMD is classified as a rare disease and many
researchers believe it is underdiagnosed; and
WHEREAS, Ninety percent of individuals affected by FMD are
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
women between 20 and 60 years of age, but men and children also
get the disease; and
WHEREAS, There are different types of FMD, with the two most
common being medial fibroplasia and intimal fibroplasia, and
there is no understanding of what causes the differences; and
WHEREAS, Children are most likely to be diagnosed with
intimal fibroplasia, a more aggressive type; and
WHEREAS, Individuals and families affected by fibromuscular
dysplasia often experience isolation and difficulty in obtaining
accurate and timely diagnoses and optimal treatment options; and
WHEREAS, FMD patients often must educate their own physicians
about the disease; and
WHEREAS, Since the Fibromuscular Dysplasia Society of America
(FMDSA) was founded in March 2003, it has been successful in
raising public and medical professional awareness, increasing
patient support and working with researchers around the world;
and
WHEREAS, FMDSA is also funding the United States Registry for
Fibromuscular Dysplasia; therefore be it
RESOLVED, That the Senate designate the month of March 2019
as "Fibromuscular Dysplasia Awareness Month" in Pennsylvania.
20190SR0052PN0488 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21